P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

• C. Y. Cheah,
• N. L. Bartlett,
• S. Assouline,
• S. J. Schuster,
• W. Seog Kim,
• M. Shadman,
• I. Isufi,
• S. Yin,
• M. Y. Doral,
• J. Sit,
• V. Chen,
• H. Huang,
• M. Zhou,
• M. C. Wei,
• L. E. Budde

Affiliations

C. Y. Cheah

1 Linear Clinical Research, Sir Charles Gairdner Hospital and The University of Western Australia, Perth, Australia

N. L. Bartlett

2 Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, United States of America

S. Assouline

3 Jewish General Hospital, Montreal, Canada

S. J. Schuster

4 University of Pennsylvania, Philadelphia, PA, United States of America

W. Seog Kim

5 Samsung Medical Centre, Seoul, South Korea

M. Shadman

6 Fred Hutchinson Cancer Research Center, Seattle, WA, Seattle, WA

I. Isufi

7 Yale School of Medicine, New Haven, CT

S. Yin

8 Genentech, Inc., South San Francisco, CA, United States of America

M. Y. Doral

8 Genentech, Inc., South San Francisco, CA, United States of America

J. Sit

8 Genentech, Inc., South San Francisco, CA, United States of America

V. Chen

8 Genentech, Inc., South San Francisco, CA, United States of America

H. Huang

9 Hoffmann-La Roche Ltd, Mississauga, Canada

M. Zhou

10 F. Hoffmann-La Roche, Shanghai, China

M. C. Wei

8 Genentech, Inc., South San Francisco, CA, United States of America

L. E. Budde

11 City of Hope, Duarte, CA, United States of America